The main results of PROactive were presented at the plenary session of the 41st Annual Meeting of the European Association for the Study for Diabetes (EASD) on 12th September 2005.

We showed that there was a non-significant 10% risk reduction in the primary end point of all-cause mortality, non-fatal MI (including silent MI), stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries and amputation above the ankle with pioglitazone relative to placebo (HR 0.90, 95% CI 0.80–1.02, p=0.095). There was a significant 16% risk reduction in the main secondary end point of all-cause mortality, non-fatal MI and stroke with pioglitazone relative to placebo (HR 0.84, 95% CI 0.72–0.98, p=0.027). These key data were published in the Lancet 2005. A copy of the paper can be downloaded by clicking here.

The webcast of the EASD plenary presentations can be viewed in its entirety or by speaker. Please click on the relevant link on the right. The full PowerPoint presentation can be viewed or downloaded in English, German, Italian or Spanish. Please click the link on the right.

At the World Congress of Cardiology (WCC) in Barcelona on 3rd September 2006, Professor Robert Wilcox presented a prespecified subgroup analysis of the 984 patients who all had previous stroke. We showed that pioglitazone significantly reduced the risk of recurrent stroke by 47% relative to placebo in this high-risk population with type 2 diabetes and previous stroke. The PowerPoint presentation can be viewed by clicking the link on the right. These data have been published in Stroke. Please click here to download the publication.